Aurobindo Pharma stock in focus after subsidiary Unit-IV receives VAI status from US FDAAurobindo Pharma stock in focus after subsidiary Unit-IV receives VAI status from US FDA

Introduction

Leading pharmaceutical company said the US Food and Drug Administration classified its subsidiary manufacturing facility in Andhra Pradesh as Voluntary Action Indicated after completing an inspection.

Also Read: Bharat Forge shares jump after partnering with Liebherr-Aerospace for advanced landing gear plant

Share price movement of Aurobindo Pharma

On March 12, 2026, Aurobindo Pharma Ltd opened at ₹1,301.20, down 0.26% from its previous close of ₹1,304.60. The stock reached a high of ₹1,318.00 (1.03%) and a low of ₹1,290.50. By 12:57 PM, it traded at ₹1,310.60, a 0.46% increase, with a market cap of ₹76,119.86 crore.

US FDA Closes Aurobindo Unit Inspection

Aurobindo Pharma Limited said the US Food and Drug Administration inspected Unit-IV of subsidiary APL Healthcare Limited in Andhra Pradesh from December 8 to December 17, 2025.

The facility received an Establishment Inspection Report from the US Food and Drug Administration with Voluntary Action Indicated classification. The inspection is now closed after the regulator earlier issued five observations.

Stock performance of Aurobindo Pharma for period of 1 week, 6 months, and 1 year

Aurobindo Pharma Ltd has delivered a 1-week return of 6.47%, a 6-month return of 19.2%, and a 1-year return of 17.8%.

Also Read: V-Guard Industries stock jumps after board approves strategic investment in GEL

Shareholding pattern of Aurobindo Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	51.80%	51.80%	51.80%
FII	14.00%	14.20%	14.40%
DII	27.70%	27.60%	26.90%
Public	6.60%	6.40%	6.90%

About Aurobindo Pharma

Aurobindo Pharma Ltd (NSE: AUROPHARMA) manufactures and markets active pharmaceutical ingredients, generic pharmaceuticals, and related services, supplying medicines to global markets through its pharmaceutical production operations.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

---